CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review

Purpose of Review The purpose of the following review is to summarize the most recent understanding of migraine pathophysiology, as well as of basic and clinical science pharmacologic literature regarding the development of calcitonin gene receptor peptide (CGRP) antagonists as a novel therapeutic m...

Full description

Saved in:
Bibliographic Details
Published in:Current pain and headache reports 2019-05, Vol.23 (5), p.29-29, Article 29
Main Authors: Urits, Ivan, Jones, Mark R., Gress, Kyle, Charipova, Karina, Fiocchi, Jacob, Kaye, Alan D., Viswanath, Omar
Format: Article
Language:English
Subjects:
Anesthesiology
Gene expression
Headaches
Internal Medicine
Medicine
Medicine & Public Health
Migraine
Monoclonal antibodies
Other Pain (A Kaye and N Vadivelu
Pain
Pain Medicine
Peptides
Plasma
Proteins
Section Editors
Topical Collection on Other Pain
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review The purpose of the following review is to summarize the most recent understanding of migraine pathophysiology, as well as of basic and clinical science pharmacologic literature regarding the development of calcitonin gene receptor peptide (CGRP) antagonists as a novel therapeutic modality for the treatment of migraine headaches. A review is provided of erenumab, the first of its class FDA approved CGRP antagonist. Recent Findings Despite its high prevalence, the occurrence and treatment of migraine headaches is poorly understood. Erenumab and CGRP antagonists as a whole significantly reduce the average number of migraine days experienced in migraine sufferers. Summary CGRP antagonists appear to significantly improve treatment outcomes in patients who suffer from episodic and chronic migraines. Erenumab is the first CGRP antagonist to be FDA approved for public use; however, further development of biologics in this class is underway.
ISSN:1531-3433
1534-3081
DOI:10.1007/s11916-019-0768-y